2003
DOI: 10.1007/s11901-003-0010-5
|View full text |Cite
|
Sign up to set email alerts
|

Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0
3

Year Published

2003
2003
2019
2019

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(15 citation statements)
references
References 60 publications
0
12
0
3
Order By: Relevance
“…This significantly enhanced both the half-life and the biologic activity of this agent when compared with standard IFN and allowed this drug to be administered once weekly. 81 When compared with standard IFN monotherapy, SVR is significantly greater when patients were treated with PEGIFN. 17,18 Treatment with the combination of PEGIFN and RBV was also significantly more effective at achieving SVR compared with standard IFN and RBV in patients with genotype 1: 40% to 45% verus 33%, respectively.…”
Section: Treatment Of Hcv Infectionmentioning
confidence: 99%
“…This significantly enhanced both the half-life and the biologic activity of this agent when compared with standard IFN and allowed this drug to be administered once weekly. 81 When compared with standard IFN monotherapy, SVR is significantly greater when patients were treated with PEGIFN. 17,18 Treatment with the combination of PEGIFN and RBV was also significantly more effective at achieving SVR compared with standard IFN and RBV in patients with genotype 1: 40% to 45% verus 33%, respectively.…”
Section: Treatment Of Hcv Infectionmentioning
confidence: 99%
“…An acknowledged shortcoming of standard interferon therapy is that the antiviral activity of interferons is limited by the fact that they only remain in the body for a short amount of time. [25][26][27] Indeed, even on three doses of interferon per…”
Section: A Case Study In Virologymentioning
confidence: 99%
“…28 However, there is good evidence of a couple of mechanisms by which pegylation prolongs the biological half-life of interferons, that is, the time it takes biological processes to remove half of the substance. 27,29,30 In particular, pegylation prolongs the half-life of the interferon by increasing its effective size, thereby decreasing renal and cell clearance. In addition, pegylation disrupts enzyme activity, which also prolongs the half-life of the interferon by decreasing proteolysis.…”
Section: A Case Study In Virologymentioning
confidence: 99%
“…Furthermore, the PEG moiety results in reduced immunogenicity and sterically hinders the antigenic binding site. 26,27 Although pegylated IFN has replaced standard IFN-a in treatment of chronic HBV and HCV, as many as 40% to 50% of patients still fail to respond to treatment. Successful response depends on many factors including but not limited to viral genotype, viral load, and degree of liver fibrosis.…”
Section: Use Of Interferons For Hepatitis Virusesmentioning
confidence: 99%